Temporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 04 04 2023
revised: 21 09 2023
accepted: 14 11 2023
pubmed: 20 11 2023
medline: 20 11 2023
entrez: 20 11 2023
Statut: ppublish

Résumé

Approximately half of patients with cancer receive radiotherapy and, as cancer survivorship increases, the low rate of radiation-associated sarcomas is rising. Pharmacologic inhibition of p53 has been proposed as an approach to ameliorate acute injury of normal tissues from genotoxic therapies, but how this might impact the risk of therapy-induced cancer and normal tissue injuries remains unclear. We utilized mice that express a doxycycline (dox)-inducible p53 short hairpin RNA to reduce Trp53 expression temporarily during irradiation. Mice were placed on a dox diet 10 days prior to receiving 30 or 40 Gy hind limb irradiation in a single fraction and then returned to normal chow. Mice were examined weekly for sarcoma development and scored for radiation-induced normal tissue injuries. Radiation-induced sarcomas were subjected to RNA sequencing. Following single high-dose irradiation, 21% of animals with temporary p53 knockdown during irradiation developed a sarcoma in the radiation field compared with 2% of control animals. Following high-dose irradiation, p53 knockdown preserves muscle stem cells, and increases sarcoma development. Mice with severe acute radiation-induced injuries exhibit an increased risk of developing late persistent wounds, which were associated with sarcomagenesis. RNA sequencing revealed radiation-induced sarcomas upregulate genes related to translation, epithelial-mesenchymal transition (EMT), inflammation, and the cell cycle. Comparison of the transcriptomes of human and mouse sarcomas that arose in irradiated tissues revealed regulation of common gene programs, including elevated EMT pathway gene expression. These results suggest that blocking p53 during radiotherapy could minimize acute toxicity while exacerbating late effects including second cancers. Strategies to prevent or mitigate acute radiation toxicities include pharmacologic inhibition of p53 and other cell death pathways. Our data show that temporarily reducing p53 during irradiation increases late effects including sarcomagenesis.

Identifiants

pubmed: 37982576
pii: 730182
doi: 10.1158/2767-9764.CRC-23-0104
pmc: PMC10697056
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2455-2467

Subventions

Organisme : NCI NIH HHS
ID : K99 CA212198
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197616
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI067798
Pays : United States

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Auteurs

Andrea R Daniel (AR)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Chang Su (C)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Nerissa T Williams (NT)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Zhiguo Li (Z)

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.

Jianguo Huang (J)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Omar Lopez (O)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Lixia Luo (L)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Yan Ma (Y)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Lorraine da Silva Campos (LDS)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Sara R Selitsky (SR)

QuantBio LLC, Durham, North Carolina.
Tempus Labs, Inc., Chicago, Illinois.

Jennifer L Modliszewski (JL)

QuantBio LLC, Durham, North Carolina.

Siyao Liu (S)

QuantBio LLC, Durham, North Carolina.
Tempus Labs, Inc., Chicago, Illinois.

Rosa Hernansaiz-Ballesteros (R)

QuantBio LLC, Durham, North Carolina.
Tempus Labs, Inc., Chicago, Illinois.

Yvonne M Mowery (YM)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Department of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, North Carolina.

Diana M Cardona (DM)

Department of Pathology, Duke University Medical Center, Durham, North Carolina.

Chang-Lung Lee (CL)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Department of Pathology, Duke University Medical Center, Durham, North Carolina.

David G Kirsch (DG)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina.

Classifications MeSH